SR-4835 Chemical Properties

Boiling point:

886.6±75.0 °C(Predicted)

Density 

1.72±0.1 g/cm3(Predicted)

storage temp. 

Store at -20°C

solubility 

DMSO:5.0(Max Conc. mg/mL);10.0(Max Conc. mM)

form 

Solid

pka

9.13±0.30(Predicted)

color 

Off-white to light brown

InChIKey

FSELUFUYNUNZKD-UHFFFAOYSA-N

SMILES

N1C2C(=NC(N3CCOCC3)=NC=2NCC2NC3=CC(Cl)=C(Cl)C=C3N=2)N(C2=CN(C)N=C2)C=1

SR-4835 Usage And Synthesis

Uses

SR-4835 is a potent, highly selective and ATP competitive dual inhibitor of CDK12/CDK13 (CDK12: IC50=99 nM, Kd=98 nM; CDK13: Kd=4.9 nM). SR-4835 acts in synergy with DNA-damaging chemotherapy and PARP inhibitors and provokes triple-negative breast cancer (TNBC) cell death[1].

IC 50

CDK12: 99 nM (IC₅₀); CDK12: 98 nM (Kd); CDK13: 4.9 nM (Kd)

References

[1] Quereda V, et al. Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer. Cancer Cell. 2019 Oct 8. pii: S1535-6108(19)30424-6. DOI:10.1016/j.ccell.2019.09.004

SR-4835(2387704-62-1)Related Product Information

• 4-Quinolinecarboxamide, N-[3-[[[2-[4-(aminosulfonyl)phenyl]ethyl]amino]carbonyl]phenyl]-1,2-dihydro-2-oxo-
• NA
• SR-717
• SRT3025
• SR9009
• SR19881
• SRPK inhibitor
• SR 1078
• N-[2-[3-(1-Piperazinylmethyl)imidazo[2,1-b]thiazol-6-yl]phenyl]-2-quinoxalinecarboxamide
• SRI 31215
• SR 0987
• SR27897
• SR17018
• SR-9243
• SR 3029
• SR 16832
• SR8278
• SR18662